Actithera
Norway
- Oslo
- 09/07/2025
- Series A
- $75,500,000
Actithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs). Founded in 2021 by drug discovery innovator Dr. Andreas Goutopoulos, and seed investors M Ventures, and Arkin Bio Ventures II, Actithera applies various molecular design strategies, including covalent-targeting and an isotope-agnostic philosophy to invent RLTs with significant differentiation and larger therapeutic windows. Headquartered in Oslo, Norway, and Cambridge, Massachusetts, Actithera is committed to advancing a differentiated pipeline addressing critical unmet needs in oncology.
- Industry Biotechnology Research
- Website https://actithera.com/
- LinkedIn https://www.linkedin.com/company/actithera/
Related People
Andreas GoutopoulosFounder
United States -
Boston, Massachusetts
Founder of Actithera, developing smarter radiopharmaceuticals to treat cancer more effectively and safely. Focused on turning chemistry and science into better outcomes for patients.
Brevo | $582,532,500 | (Dec 5, 2025)
Lumia Security | $18,000,000 | (Dec 5, 2025)
imper.ai | $28,000,000 | (Dec 5, 2025)
IMTC | $12,000,000 | (Dec 5, 2025)
Govstream.ai | $3,600,000 | (Dec 5, 2025)
SPhotonix Inc | $4,500,000 | (Dec 5, 2025)
Unlimited Industries | $12,000,000 | (Dec 5, 2025)
Paradigm Health | $78,000,000 | (Dec 5, 2025)
Guide Labs | $9,000,000 | (Dec 5, 2025)
7AI | $130,000,000 | (Dec 5, 2025)
Ply | $8,500,000 | (Dec 5, 2025)
Find Your Grind | $5,000,000 | (Dec 5, 2025)